Jiangsu Hengrui Medicine Uses Partnerships to Advance Novel Drug Programs

In September 2015, Jiangsu Hengrui Medicine made history by out-licensing global rights (not including China) to its PD-1 cancer immunotherapy. Incyte, a US oncology pharma, acquired the rights in a deal worth up to $795 million if Hengrui collects all the milestones, the largest amount ever paid for a single China pharma asset. The deal underscores the tremendous progress the China biopharma industry, and Hengrui in particular, has made in transforming into a global developer of novel drugs. Lianshan Zhang, PhD, President of Global R&D at Hengrui and a bona fide sea turtle or hai gui , told ChinaBio® Today in an exclusive interview that Incyte is a very good fit for Hengrui's PD-1 molecule. More details.... Share this with colleagues: // //